

# Pregnancy outcomes and risk of endometrial cancer

Citation for published version (APA):

Jordan, S. J., Na, R., Weiderpass, E., Adami, H.-O., Anderson, K. E., van den Brandt, P. A., Brinton, L. A., Chen, C., Cook, L. S., Doherty, J. A., Du, M., Friedenreich, C. M., Gierach, G. L., Goodman, M. T., Krogh, V., Levi, F., Lu, L., Miller, A. B., McCann, S. E., ... Webb, P. M. (2021). Pregnancy outcomes and risk of endometrial cancer: A pooled analysis of individual participant data in the Epidemiology of Endometrial Cancer Consortium. *International Journal of Cancer*, 148(9), 2068-2078. <https://doi.org/10.1002/ijc.33360>

**Document status and date:**

Published: 01/05/2021

**DOI:**

[10.1002/ijc.33360](https://doi.org/10.1002/ijc.33360)

**Document Version:**

Publisher's PDF, also known as Version of record

**Document license:**

Taverne

**Please check the document version of this publication:**

- A submitted manuscript is the version of the article upon submission and before peer-review. There can be important differences between the submitted version and the official published version of record. People interested in the research are advised to contact the author for the final version of the publication, or visit the DOI to the publisher's website.
- The final author version and the galley proof are versions of the publication after peer review.
- The final published version features the final layout of the paper including the volume, issue and page numbers.

[Link to publication](#)

**General rights**

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain.
- You may freely distribute the URL identifying the publication in the public portal.

If the publication is distributed under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license above, please follow below link for the End User Agreement:

[www.umlib.nl/taverne-license](http://www.umlib.nl/taverne-license)

**Take down policy**

If you believe that this document breaches copyright please contact us at:

[repository@maastrichtuniversity.nl](mailto:repository@maastrichtuniversity.nl)

providing details and we will investigate your claim.

# Pregnancy outcomes and risk of endometrial cancer: A pooled analysis of individual participant data in the Epidemiology of Endometrial Cancer Consortium

Susan J. Jordan<sup>1,2</sup>  | Renhua Na<sup>1</sup>  | Elisabete Weiderpass<sup>3</sup>  |  
 Hans-Olov Adami<sup>4,5</sup> | Kristin E. Anderson<sup>6,7</sup>  | Piet A. van den Brandt<sup>8</sup>  |  
 Louise A. Brinton<sup>9</sup>  | Chu Chen<sup>10</sup>  | Linda S. Cook<sup>11</sup>  |  
 Jennifer A. Doherty<sup>10,12</sup>  | Mengmeng Du<sup>13</sup> | Christine M. Friedenreich<sup>14,15</sup>  |  
 Gretchen L. Gierach<sup>16</sup>  | Marc T. Goodman<sup>17</sup> | Vittorio Krogh<sup>18</sup>  | Fabio Levi<sup>19</sup> |  
 Lingeng Lu<sup>20</sup>  | Anthony B. Miller<sup>21</sup>  | Susan E. McCann<sup>22</sup>  |  
 Kirsten B. Moysich<sup>22</sup> | Eva Negri<sup>23</sup>  | Sara H. Olson<sup>13</sup> | Stacey Petruzzella<sup>13</sup> |  
 Julie R. Palmer<sup>24,25</sup>  | Fabio Parazzini<sup>26,27</sup> | Malcolm C. Pike<sup>13</sup>  |  
 Anna E. Prizment<sup>7,28</sup> | Timothy R. Rebbeck<sup>29</sup> | Peggy Reynolds<sup>30</sup>  |  
 Fulvio Ricceri<sup>31</sup>  | Harvey A. Risch<sup>20</sup> | Thomas E. Rohan<sup>32</sup> |  
 Carlotta Sacerdote<sup>33</sup>  | Leo J. Schouten<sup>8</sup>  | Diego Serraino<sup>34</sup>  |  
 Veronica W. Setiawan<sup>35</sup>  | Xiao-Ou Shu<sup>36</sup>  | Todd R. Sponholtz<sup>24,25</sup> |  
 Amanda B. Spurdle<sup>1,37</sup>  | Rachael Z. Stolzenberg-Solomon<sup>38</sup>  |  
 Britton Trabert<sup>38</sup>  | Nicolas Wentzensen<sup>39</sup>  | Lynne R. Wilkens<sup>40</sup> |  
 Lauren A. Wise<sup>41</sup>  | Herbert Yu<sup>42</sup>  | Carlo La Vecchia<sup>26</sup>  |  
 Immaculata De Vivo<sup>43,44</sup>  | Wanghong Xu<sup>45</sup>  | Anne Zeleniuch-Jacquotte<sup>46</sup>  |  
 Penelope M. Webb<sup>1,2</sup> 

<sup>1</sup>Population Health Department, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia

<sup>2</sup>School of Public Health, University of Queensland, Brisbane, Queensland, Australia

<sup>3</sup>Director's Office, International Agency for Research on Cancer, World Health Organization, Lyon, France

<sup>4</sup>Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden

<sup>5</sup>Clinical Effectiveness Research Group, Institute of Health and Society, University of Oslo, Oslo, Norway

<sup>6</sup>School of Public Health, Division of Epidemiology & Community Health, University of Minnesota, Minneapolis, Minnesota

<sup>7</sup>Screening, Prevention, Etiology and Cancer Survivorship Program, University of Minnesota Masonic Cancer Center, Minneapolis, Minnesota

<sup>8</sup>Department of Epidemiology, GROW-School for Oncology and Developmental Biology, Maastricht University, Maastricht, The Netherlands

<sup>9</sup>Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland

<sup>10</sup>Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington

<sup>11</sup>Division of Epidemiology, Biostatistics & Preventive Medicine, Department of Internal Medicine, NM Health Sciences Center, University of New Mexico, University of New Mexico, Albuquerque, New Mexico

<sup>12</sup>Department of Population Health Sciences, Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah

<sup>13</sup>Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York

- <sup>14</sup>Department of Cancer Epidemiology and Prevention Research, Cancer Care Alberta, Alberta Health Services, Calgary, Alberta, Canada
- <sup>15</sup>Departments of Oncology and Community Health Sciences, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada
- <sup>16</sup>Integrative Tumor Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland
- <sup>17</sup>Cancer Prevention and Control Program, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, California
- <sup>18</sup>Epidemiology and Prevention Unit, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy
- <sup>19</sup>Department of Epidemiology and Health Services Research, Centre for Primary Care and Public Health (Unisanté), University of Lausanne, Lausanne, Switzerland
- <sup>20</sup>Department of Chronic Disease Epidemiology, Yale School of Public Health, New Haven, Connecticut
- <sup>21</sup>Epidemiology Division, Dalla Lana School of Public Health, Toronto, Ontario, Canada
- <sup>22</sup>Department of Cancer Prevention and Control, Roswell Park Comprehensive Cancer Center, Buffalo, New York
- <sup>23</sup>Department of Biomedical and Clinical Sciences, Università degli Studi di Milano, Milan, Italy
- <sup>24</sup>Sloan Epidemiology Center at Boston University, Boston, Massachusetts
- <sup>25</sup>Department of Medicine, Boston University School of Medicine, Boston, Massachusetts
- <sup>26</sup>Department of Clinical Sciences and Community Health, Università degli Studi di Milano, Milan, Italy
- <sup>27</sup>Department of Obstetrics and Gynaecology, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy
- <sup>28</sup>Division of Hematology, Oncology and Transplantation, University of Minnesota, Minneapolis, Minnesota
- <sup>29</sup>Division of Population Science, Dana-Farber Cancer Institute and Harvard TH Chan School of Public Health, Boston, Massachusetts
- <sup>30</sup>Department of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, California
- <sup>31</sup>Department of Clinical and Biological Sciences, University of Turin, Orbassano, Italy
- <sup>32</sup>Department of Epidemiology and Population Health, Albert Einstein College of Medicine, Bronx, New York
- <sup>33</sup>Unit of Cancer Epidemiology, Città della Salute e della Scienza University-Hospital and Center for Cancer Prevention (CPO), Turin, Italy
- <sup>34</sup>Cancer Epidemiology Unit, Centro di Riferimento Oncologico IRCCS, Aviano, Italy
- <sup>35</sup>Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California
- <sup>36</sup>Division of Epidemiology, Department of Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee
- <sup>37</sup>Genetics and Computational Biology Department, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia
- <sup>38</sup>Metabolic Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland
- <sup>39</sup>Division of Cancer Epidemiology and Genetics, Clinical Genetics Branch, National Cancer Institute, Bethesda, Maryland
- <sup>40</sup>Epidemiology Program, University of Hawaii Cancer Center, Honolulu, Hawaii
- <sup>41</sup>Department of Epidemiology, Boston University School of Public Health, Boston, Massachusetts
- <sup>42</sup>Epidemiology Program, University of Hawaii Cancer Center, Honolulu, Hawaii
- <sup>43</sup>Department of Medicine, Channing Division of Network Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts
- <sup>44</sup>Department of Epidemiology, Harvard T. H. Chan School of Public Health, Boston, Massachusetts
- <sup>45</sup>Department of Epidemiology, Fudan University School of Public Health, Shanghai, China
- <sup>46</sup>Department of Population Health and Perlmutter Cancer Center, New York University Langone Health, New York, New York

#### Correspondence

Penelope M. Webb, Population Health  
 Department, QIMR Berghofer Medical Research Institute, 300 Herston Road, Herston, QLD, 4006, Australia.  
 Email: penny.webb@qimrberghofer.edu.au

#### Funding information

Alberta Heritage Foundation for Medical Research; Associazione Italiana per la Ricerca sul Cancro; California Department of Public Health; Canadian Breast Cancer Research Alliance; Canadian Cancer Society; Canadian Institutes of Health Research; Cancer Council Tasmania, Grant/Award Numbers: 403031, 457636; Centers for Disease Control and Prevention's National Program of Cancer Registries; Health and Welfare Canada; Intramural Research Program of the National Cancer Institute/National Institutes of Health,

#### Abstract

A full-term pregnancy is associated with reduced endometrial cancer risk; however, whether the effect of additional pregnancies is independent of age at last pregnancy is unknown. The associations between other pregnancy-related factors and endometrial cancer risk are less clear. We pooled individual participant data from 11 cohort and 19 case-control studies participating in the Epidemiology of Endometrial Cancer Consortium (E2C2) including 16 986 women with endometrial cancer and 39 538 control women. We used one- and two-stage meta-analytic approaches to estimate pooled odds ratios (ORs) for the association between exposures and endometrial cancer risk. Ever having a full-term pregnancy was associated with a 41% reduction in risk of endometrial cancer compared to never having a full-term pregnancy (OR = 0.59, 95% confidence interval [CI] 0.56-0.63). The risk reduction appeared the greatest for the first full-term pregnancy (OR = 0.78, 95% CI 0.72-0.84), with a further ~15%

Department of Health and Human Services, United States; Italian League Against Cancer; KWF Kankerbestrijding; le Ministère de la Santé et des Services Sociaux du Québec; Nova Scotia Department of Health; Manitoba Health Services Commission; Medical Research Council Canada; Memorial Sloan Kettering NCI Support Grant, Grant/Award Number: P30 CA008748; National Cancer Institute, Grant/Award Numbers: 2R01 CA082838, P01 CA87969, CA11535, N01-CN-05223, N01-CN-55424, P01-CA77596, P30CA016056, P30CA118100, R01 CA081212, U01 CA182934, P30 CA016087, R01 CA083918, R01 CA092585, R01 CA39742, R01 CA48774, P30 CA14089, R01 CA058420, U01 CA164974, R03 CA169888, R01 CA098346, R01 CA77398, R35 CA39779, R01 CA47749, R01 CA75977, N01 HD 2 31, U01 CA164973, RO3 CA135632; National Cancer Institute of Canada; National Health and Medical Research Council, Grant/Award Numbers: APP339435, APP1073898, APP1061341, APP1061779, ID 1061778, GNT 1073898; National Institutes of Health, Grant/Award Number: R01 CA74877; Ontario Ministry of Health; Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung, Grant/Award Number: 32.9495.88; Krebsforschung Schweiz Stiftung, Grant/Award Number: OCS 1633-02-2005; U.S. Public Health Service, Grant/Award Numbers: P01-CA-33619, R01-CA-58598, R01-CA-55700, P20-CA-57113; Vetenskapsrådet, Grant/Award Number: 521-2011-2955

reduction per pregnancy up to eight pregnancies ( $OR = 0.20$ , 95% CI 0.14-0.28) that was independent of age at last full-term pregnancy. Incomplete pregnancy was also associated with decreased endometrial cancer risk (7%-9% reduction per pregnancy). Twin births appeared to have the same effect as singleton pregnancies. Our pooled analysis shows that, while the magnitude of the risk reduction is greater for a full-term pregnancy than an incomplete pregnancy, each additional pregnancy is associated with further reduction in endometrial cancer risk, independent of age at last full-term pregnancy. These results suggest that the very high progesterone level in the last trimester of pregnancy is not the sole explanation for the protective effect of pregnancy.

#### KEY WORDS

endometrial cancer, induced abortion, miscarriage, parity, sex of offspring

## 1 | INTRODUCTION

Full-term pregnancy is associated with reduced endometrial cancer risk,<sup>1</sup> although the mechanism underlying the association is not well understood. It has been suggested that hormonal factors may underpin the relationship,<sup>2</sup> because progestins can potentially reverse premalignant changes in the endometrium<sup>3</sup> and progesterone levels are very high during pregnancy.<sup>4</sup> Alternatively, it has been suggested that the physical shedding of the endometrium at childbirth may remove preneoplastic endometrial cells.<sup>5</sup> Greater understanding of the relationship between other pregnancy-related factors and endometrial cancer risk will increase our understanding of the mechanisms underlying the protective effects of full-term pregnancy.

Although most epidemiological studies indicate that additional full-term pregnancies up to at least four are associated with progressive reductions in endometrial cancer risk, few studies have had sufficient power to investigate whether subsequent pregnancies beyond this further reduce risk and their results have not been consistent. One showed no further risk reduction after six births;<sup>6</sup> one showed that risk continued to decline up to at least 10 births;<sup>7</sup> and another showed smaller, nonsignificant risk reductions for the fifth birth.<sup>8</sup> In addition, studies have shown that older age at last full-term pregnancy is associated with lower risk of endometrial

#### What's new?

Having a full-term pregnancy reduces a woman's risk of endometrial cancer, perhaps due to a protective effect from high levels of progesterone in the third trimester. Here, the authors conducted a pooled analysis of 11 cohort studies and 19 case-control studies to learn more about the effect of multiple pregnancies on endometrial cancer risk. They found that up to eight full-term pregnancies each reduced endometrial cancer risk, independent of maternal age and oral contraceptive use. Interestingly, incomplete pregnancies were associated with a smaller reduction in risk, suggesting that high third trimester progesterone levels are not the only contributing factor.

cancer<sup>9</sup>; therefore, the reduced risk associated with increasing numbers of full-term pregnancies may just reflect later age at last full-term pregnancy. However, this has not been adequately explored.

The associations between other pregnancy-related factors, such as incomplete pregnancy (spontaneous or induced abortion), multiple birth (eg, twins) and sex of offspring and endometrial cancer have also been infrequently investigated and results were mixed. Some<sup>8,10-12</sup> but not all<sup>2,13-15</sup> studies suggest incomplete pregnancies are associated with reduced risk, but most included small numbers of exposed case women. Differences have also been observed for spontaneous vs induced pregnancy loss.<sup>8,16,17</sup> In particular, a recent Danish data linkage study found that induced abortion was associated with an ~50% reduction in endometrial cancer risk, whereas the risk reduction associated with a miscarriage was much smaller and not statistically significant.<sup>8</sup> However, they were unable to adjust for important potential confounders including contraceptive use and smoking status.

To assess the association between pregnancy outcomes and endometrial cancer risk in detail, we pooled data from 30 observational studies (cohort and case-control; 16 986 women with endometrial cancer and 39 538 controls) participating in the Epidemiology of Endometrial Cancer Consortium (E2C2). We hypothesized that if progesterone is responsible for the previously observed inverse associations, endometrial cancer risk would decrease with each subsequent full-term pregnancy; risk would also decrease for incomplete pregnancies, but to a lesser extent. Risk reduction with twin birth might be greater because of higher progesterone levels, and risk might differ by offspring sex because of differences in maternal hormone levels.<sup>18,19</sup> However, if shedding of the endometrium is the underlying mechanism, we hypothesized the risk reduction would be similar for all types of pregnancy.

## 2 | MATERIALS AND METHODS

### 2.1 | Participants and data collection

We included 11 cohort and 19 case-control studies with individual participant data on pregnancy outcomes including numbers of full-term pregnancies, incomplete pregnancies (miscarriages and induced abortions), twin/multiple births and sex of babies. All studies had institutional review board approval and participants provided informed consent. The E2C2 data harmonization process has been described elsewhere.<sup>20</sup> In brief, studies provided information on demographic, anthropometric, and lifestyle factors (eg, height, weight 1-5 years before diagnosis, oral contraceptive (OC) and menopausal hormone therapy (MHT) use and smoking) according to specified definitions.

For the current analyses, cohort studies were analyzed as nested case-control studies with up to four controls per case, matched on year of birth, cohort entry date and other study-specific criteria as appropriate, randomly selected from cohort members without a hysterectomy or endometrial cancer by the case diagnosis date. We excluded cases (and, for cohort studies, their matched controls) with nonepithelial tumors or tumors of unknown histology (179 cases/418 controls), and women missing data for all pregnancy outcomes (549 cases/438 controls, including controls individually matched to cases with missing data). The remaining eligible participants included 16 986 women with endometrial cancer and 39 538 controls.

### 2.2 | Exposures

Data on full-term pregnancies (defined by E2C2 as at least 7 months duration) including both livebirths and stillbirths were provided by 22 of the 30 studies (Supplementary Table 1 for full study names). Eight studies (ALBERTA, BCDDP, CNBSS, MEC, NHS, NLCS, ORDET and TURIN) provided information on livebirths but not stillbirths, hence livebirths was used as a proxy for full-term pregnancies; a sensitivity analysis excluding these studies gave essentially the same results. The total number of incomplete pregnancies (miscarriages + induced abortions) was provided by 16 studies (ANECS, BWHS, CONN, EDGE, FHCRC, IMS, IWHS, ML1, ML2, NYU, PEDS, POL, SECS, TURIN, VAUD and WNYDS) or estimated as total number of pregnancies minus number of full-term pregnancies/livebirths. Five studies provided the number of daughters and sons (ANECS, CONN, EDGE, FHCRC and TURIN). Another five (IWHS, PEDS, POL, SECS and USC) provided the number of daughters; therefore, the number of sons was estimated as the number of livebirths minus the number of daughters. Seven studies provided data on twin/multiple births (ANECS, BWHS, CONN, EDGE, FHCRC, TURIN and WNYDS). All pregnancy data were self-reported.

### 2.3 | Statistical analysis

We initially used two-stage individual-participant meta-analysis to estimate risk per full-term or incomplete pregnancy. We estimated study-specific odds ratios (OR) and 95% confidence intervals (CI) using multivariable logistic regression (conditional logistic regression for matched studies). Models were adjusted for age at diagnosis (cases) or interview (controls) (<40, 40-49, 50-59, 60-69, 70+ years), BMI ( $\text{kg}/\text{m}^2$ , continuous), education (<high school, technical college, university), smoking (never, former, current) and OC use (never, ever; further adjustment for duration in studies with this information made little difference). Analyses of the relation between incomplete pregnancies and endometrial cancer risk were further adjusted for a number of full-term pregnancies (continuous). The proportion of missing data on confounders ranged from 0.6% for education to 3% for BMI with a total of 6% of women missing data on  $\geq 1$  variable. These women were excluded from study-specific analyses. Study-specific estimates were pooled using random-effects models to calculate summary ORs. Heterogeneity was assessed using  $I^2$  and Q statistics.<sup>21</sup> If substantial heterogeneity was identified, we performed a sensitivity analysis removing one study at a time to investigate the influence of individual studies.

We examined the effects of other potential confounders including age at menarche, early adult BMI, race, age at last full-term pregnancy and breastfeeding, but these did not materially alter the magnitude of the associations (Supplementary Table 2).

Given the limited heterogeneity between studies, we conducted all other analyses in one-stage model using generalized linear mixed regression models to allow the exposure effect to vary by study. One- and two-stage approaches produce similar estimates, but the

one-stage approach provides greater flexibility to evaluate interactions and undertake subgroup analyses.<sup>22</sup> This approach was used to assess the associations between endometrial cancer risk and each additional full-term or incomplete pregnancy after the first, offspring sex and twin/multiple births. We also used one-stage meta-analysis for stratified analyses to assess whether the magnitude of the association per full-term or incomplete pregnancy varied by age at diagnosis/interview, race, BMI, smoking, OC use, menopausal status and use of MHT (among postmenopausal women), age at last full-term pregnancy and histological subtype (type 1 vs type 2).<sup>20</sup> For incomplete pregnancies, we also stratified by number of full-term pregnancies.


In our main analyses, the reference group was women who never had a full-term pregnancy (for analyses of full-term pregnancy) or women who never had an incomplete pregnancy (for analyses of incomplete pregnancy). We conducted sensitivity analyses using women who had never been pregnant (nulligravid) as the reference. We also assessed the impact of subsequent pregnancies after the first by excluding nulliparous women from the full-term pregnancies analyses and examined endometrial cancer risk per incomplete pregnancy separately in nulliparous and parous women. As the results were similar, we have presented results based on the entire study population

(including nulliparous and nulligravid women) unless otherwise specified.

We calculated statistics for linear trend across ordinal categorical variables and assessed interactions between full-term and incomplete pregnancies using log-likelihood test statistics, where models with and without interaction terms were compared. We calculated Woolf's statistic for homogeneity of ORs to assess differences in estimates between case subgroups. Analyses were conducted using SAS version 9.4 (SAS Institute, Cary, North Carolina) and Stata version 15 (StataCorp LP, College Station, Texas).

### 3 | RESULTS

The characteristics of the included studies and the prevalence of pregnancy outcomes in controls are presented in Supplementary Table 1. The proportion of controls who reported at least one full-term pregnancy ranged from 67% to 96%, and the proportion who reported an incomplete pregnancy ranged from 28% to 68%. Among parous control women, the prevalence of twin births was 2% to 4%.



**FIGURE 1** Forest plot showing adjusted estimates and 95% confidence intervals for the risk of endometrial cancer per full-term pregnancy

**TABLE 1** Associations between number of full-term pregnancies and risk of endometrial cancer

Variable	Full-term pregnancy Controls n (%)	Cases n (%)	OR <sup>a</sup>	95% CI
Any vs none				
No full-term pregnancies	4955 (13)	3121 (18)	1.00	—
At least one full-term pregnancy	34 468 (87)	13 819 (82)	0.59	(0.56 to 0.63)
Number of full-term pregnancies vs none				
1	5522 (14)	2777 (16)	0.78	(0.72 to 0.84)
2	11 866 (30)	4910 (29)	0.65	(0.61 to 0.69)
3	8370 (21)	3260 (19)	0.55	(0.52 to 0.59)
4	4548 (12)	1634 (9.6)	0.49	(0.45 to 0.53)
5	2078 (5.3)	689 (4.1)	0.43	(0.39 to 0.48)
6	950 (2.4)	313 (1.8)	0.39	(0.34 to 0.46)
7	675 (1.7)	133 (0.8)	0.25	(0.20 to 0.30)
8	253 (0.6)	50 (0.3)	0.20	(0.14 to 0.28)
9+	206 (0.5)	53 (0.3)	0.27	(0.20 to 0.37)
P trend				<.001
Per full-term pregnancy—all women	39 423	16 940	0.84	(0.83 to 0.85)
Per full-term pregnancy—excluding nulliparous women	34 468	13 819	0.85	(0.84 to 0.87)

Abbreviations: CI, confidence interval; OR: odds ratio.

<sup>a</sup>One-stage models adjusted for age at diagnosis or interview (<40, 40-49, 50-59, 60-69, 70+), BMI at diagnosis or interview ( $\text{kg}/\text{m}^2$ , continuous), education (≤high school, technical college, university), smoking (never, former, current) and OC use (never, ever). Includes all studies; for ALBERTA, BCDDP, CNBSS, MEC, NHS, NLCS, ORDET and TURIN, livebirth was used as a proxy for full-term pregnancies.

Figure 1 shows that each full-term pregnancy was associated with a 15% reduction in endometrial cancer risk. This association was slightly stronger for case-control (OR = 0.84, 95% CI 0.82-0.86) than cohort studies (OR = 0.88, 95% CI 0.86-0.89). There was significant heterogeneity in results from case-control studies ( $I^2 = 50\%$ ,  $p$  heterogeneity = 0.007) due to the POL study. After excluding POL, the overall pattern remained (OR = 0.85, 95% CI 0.83-0.87) and the heterogeneity was no longer significant ( $I^2 = 25\%$ ,  $P = .1$ ).

Table 1 shows that each additional full-term pregnancy was associated with progressively reduced risk up to eight full-term pregnancies (OR = 0.20, 95% CI 0.14-0.28) although the risk reduction appeared the greatest for the first birth (OR = 0.78, 95% CI 0.72-0.84) compared to an average 15% reduction in risk (OR = 0.85, 95% CI 0.84-0.87) for each birth after the first (ie, excluding nulliparous women).

Supplementary Figure 1 shows the association per full-term pregnancy stratified by participant and tumor characteristics. Notably, the inverse association seen overall was present across all categories of age at last full-term pregnancy. The inverse associations were also seen for all strata of age, race, BMI, smoking, OC use, menopausal status, MHT use and tumor type but the association attenuated with increasing age; appeared stronger in white women than black women; and for Type 1 vs Type 2 endometrial cancer.


Meta-analysis of study-specific results in Figure 2 shows that each incomplete pregnancy was associated with a 9% reduction in endometrial cancer risk (OR = 0.91, 95% CI 0.88-0.95). Estimates did

not vary by study design (case-control studies OR = 0.92, 95% CI [0.88-0.95]; cohort studies OR = 0.90, 95% CI [0.79-1.03]). Excluding POL removed the heterogeneity ( $I^2 = 18\%$ ,  $P = .2$ ) and did not change the estimate.

Table 2 shows the estimates for each additional incomplete pregnancy. The estimate per pregnancy was slightly closer to the null in the one-stage vs the two-stage model (7% vs 9% risk reduction) although the confidence intervals were overlapping. Estimates were similar for parous and nulliparous women ( $p$  for heterogeneity = 0.7). Inverse associations were seen for both spontaneous (OR = 0.83, 95% CI 0.76-0.90 for ever vs never) and induced abortions (OR = 0.89, 95% CI 0.79-1.01 for ever vs never). Neither the association with spontaneous abortions nor the association with induced abortions differed appreciably by study design.

Supplementary Figure 2 shows the association between incomplete pregnancy and risk of endometrial cancer stratified by participant and tumor characteristics. The inverse association did not vary by age group, race, BMI, smoking status, OC use, menopausal status or type of endometrial cancer.

With respect to other pregnancy variables, we found that the risk reduction per full-term pregnancy was similar irrespective of the sex of the child (OR = 0.85, 95% CI 0.82-0.89 for girls; OR = 0.83, 95% CI 0.79-0.86 for boys); however, women who had only boys or a mix of boys and girls had a lower risk of endometrial cancer compared with women with only girls (Table 3). This pattern remained when we restricted to women with only two children. The association did not



**TABLE 2** Associations between number of incomplete pregnancies and risk of endometrial cancer

Variables	Controls <sup>a</sup>	Cases <sup>a</sup>	OR <sup>b</sup>	95% CI
<b>Any vs none</b>				
No incomplete pregnancies	15 233 (64)	8370 (67)	1.00	—
At least one incomplete pregnancy	8493 (36)	4042 (33)	0.87	(0.82 to 0.92)
<b>Number of incomplete pregnancies vs none</b>				
1	5110 (21)	2516 (20)	0.89	(0.84 to 0.95)
2	2078 (9)	981 (8)	0.86	(0.78 to 0.94)
3	787 (3.3)	339 (2.7)	0.82	(0.71 to 0.95)
4	287 (1.2)	105 (0.9)	0.75	(0.58 to 0.96)
5	108 (0.4)	55 (0.4)	0.79	(0.55 to 1.14)
6	123 (0.5)	46 (0.4)	0.69	(0.47 to 1.02)
<b>P trend</b>				<.001
Per incomplete pregnancy—all women	23 726	12 412	0.93	(0.90 to 0.95)
Per incomplete pregnancy—parous	20 494	10 051	0.93	(0.91 to 0.96)
Per incomplete pregnancy—nulliparous	3228	2352	0.95	(0.87 to 1.02)

Abbreviations: CI, confidence interval; OR, odds ratio.

<sup>a</sup>Numbers may not sum to total because of missing data.

<sup>b</sup>One-stage models adjusted for age at diagnosis or interview (<40, 40-49, 50-59, 60-69, 70+), BMI at diagnosis or interview (kg/m<sup>2</sup>, continuous), education (≤high school, technical college, university), smoking (never, former, current), OC use (never, ever) and number of full-term pregnancies (continuous). Includes data from ANECS, BAWHS, BWHS\*, CNBSS\*, CONN, CTS\*, EDGE, FHCRC, HAWAII, IMS, IWHS\*, ML1, ML2, PEDS, POL, SECS, TURIN, USC, USEC, VAUD, WISE and WNYDS. Note: Asterisk (\*) indicates cohort study.

**TABLE 3** Associations between sex of babies, twin births and endometrial cancer among parous women

Variables	Controls N (%)	Cases N (%)	OR	95% CI
<b>Sex of babies<sup>a</sup></b>				
Per daughter	7273	4952	0.85	(0.82 to 0.89)
Per son	7273	4952	0.83	(0.79 to 0.86)
<b>Sex of babies<sup>b</sup></b>				
Daughter(s) only	1809 (24)	1361 (26)	1.00	—
Son(s) only	1402 (19)	1001 (19)	0.88	(0.78 to 0.99)
Son(s) and daughter(s)	4318 (57)	2796 (54)	0.89	(0.80 to 0.99)
Restricting to women with two children				
Two daughters	639 (24)	463 (25)	1.00	—
Two sons	553 (20)	387 (20)	0.88	(0.72-1.08)
One son and one daughter	1520 (56)	1040 (55)	0.89	(0.76-1.05)
<b>Multiple births<sup>a</sup></b>				
No multiple birth	2691 (97)	2663 (96)	1.00	—
At least one multiple birth	83 (3)	99 (4)	1.10	(0.79 to 1.53)
Girl-girl	23 (0.8)	30 (1)	0.98	(0.52 to 1.82)
Boy-boy	18 (0.7)	24 (0.9)	1.23	(0.61 to 2.48)
Boy-girl	22 (0.8)	24 (0.9)	1.11	(0.57 to 2.16)

Abbreviations: CI, confidence interval; OR, odds ratio.

<sup>a</sup>Adjusted for age at diagnosis or interview (<40, 40-49, 50-59, 60-69, 70+), BMI at diagnosis or interview ( $\text{kg}/\text{m}^2$ , continuous), education (≤high school, technical college and university), smoking (never, former and current), OC use (ever, never).

<sup>b</sup>Further adjusted for number of full-term pregnancies (continuous). Includes data from ANECS, CONN, EDGE, FHCRC, IWHS\*, PEDS, POL, SECS, TURIN and USC; multiple births analysis included data from ANECS, CONN, EDGE, FHCRC, TURIN and WNY. Note: Asterisk (\*) indicates cohort study.

differ between women who had a twin/multiple birth and those who had only singleton births.

#### 4 | DISCUSSION

In this large pooled analysis, we observed a reduction in endometrial cancer risk associated with full-term pregnancy that was the greatest for the first full-term pregnancy but also evident for each subsequent full-term pregnancy up to eight. The inverse association was independent of age at last full-term pregnancy and was consistent across strata of BMI, smoking, OC use, menopausal status and MHT use, but stronger among younger women and white women. The association also appeared stronger for Type 1 than for Type 2 cancers. Incomplete pregnancy was also associated with reduced risk although the reduction per additional pregnancy was smaller than for full-term pregnancies (7% vs 15%). We found no evidence that twin births conferred additional protection compared to singleton births, but our results suggested having boys might confer somewhat greater risk reduction than having only girls.

Strengths of our study include the large sample size, which allowed us to assess associations with higher numbers of full-term and incomplete pregnancies and to compare across the different endometrial cancer subtypes. Our pooled design allowed us to define exposures and confounders consistently across studies and to include

previously published<sup>12,13,16,17,23,24</sup> and unpublished studies (ALBERTA, ANECS, BAWHS, BCDDP, BWHS, CNBSS, CONN, CTS, EDGE, FHCRC, HAWAII, IMS, MEC, NLCS, NHS, NYU, ORDET, PEDS, SWLHS, TURIN, USC, VAUD and WNYDS) from diverse populations. We also included data from both cohort and case-control studies; the patterns of results and estimates were consistent by study design, providing additional reassurance about the validity of our findings. A limitation is that for most studies we did not have information on length of gestation so could not investigate the possibility that the magnitude of the association is a function of pregnancy duration. Also, all studies relied on participant recall of exposures. Although this is likely to be very accurate for full-term pregnancies, self-report of incomplete pregnancies is less reliable. However, the similarity in pooled estimates between the case-control and cohort studies makes appreciable recall bias unlikely. If anything, misclassification may have biased our results toward the null, meaning that we may have underestimated the magnitude of the risk reduction associated with incomplete pregnancy. We also did not have information on how women with incomplete pregnancy were managed and whether they had any associated procedures. Finally, despite our very large sample, few women reported twin births, so we had limited ability to draw conclusions about any association between these and endometrial cancer.

Our findings are consistent with results from a data linkage study from Sweden, which indicated that endometrial cancer risk continues to decrease with each additional full-term pregnancy in women with

more than five births.<sup>7</sup> However, an earlier study from Finland<sup>6</sup> suggested that risk did not decrease further after the sixth full-term pregnancy once age at last full-term pregnancy was considered. They also found that in women <50 years, risk of endometrial cancer was increased in those with seven or more full-term pregnancies, but this was based on small numbers of women and was not statistically significant. We found a similar risk reduction per full-term pregnancy irrespective of age at last full-term pregnancy and found that the inverse association per full-term pregnancy was strongest (~42% reduction in risk per pregnancy) among the youngest women. Our findings were based on a larger sample size with adjustment for a wider range of potentially important confounders. Some previous studies have reported that incomplete pregnancy was associated with reduced risk of endometrial cancer<sup>8,10-12</sup> but others have not,<sup>2,13-15</sup> although most of these included small numbers of exposed case women (mostly <250 vs >4000 in our study). One large data linkage study from Denmark (n = 872 cases with an induced abortion) found that the risk reduction associated with a first induced abortion (RR = 0.53) was of greater magnitude than for a first-term pregnancy (RR = 0.66)<sup>8</sup> and that while the first miscarriage was also associated with reduced endometrial cancer risk, the magnitude of the reduction was smaller than for induced abortion. Possible explanations for the differences between their findings and ours might include differences in the methods of ascertainment of induced abortions (through data linkage rather than recall); inability to adjust for potentially important confounders such as OC use and smoking; or differences in management of incomplete pregnancy across different settings.

The mechanism responsible for the risk-reducing association with pregnancy is not clear, with some it is due to the effects of reproductive hormones during and subsequent to pregnancy, and others hypothesizing that shedding of the endometrium at the end of pregnancy removes premalignant or malignant cells.<sup>5</sup> Parous women may have lower estradiol levels than nulliparous women,<sup>25</sup> an effect that may persist into postmenopausal years and become more pronounced with increasing numbers of births.<sup>26</sup> As estrogen unopposed by a progestin increases endometrial cell mitoses,<sup>27</sup> the substantial reduction in endometrial cancer that we have observed with multiparity might reflect pervasively lower estradiol levels in these women compared to women with fewer pregnancies. Progesterone reduces estrogen-induced mitotic activity in endometrial cells and promotes cell differentiation,<sup>5,27</sup> and, as serum progesterone levels increase throughout pregnancy to very high levels in the third trimester,<sup>4</sup> the protective effects of multiparity may also reflect recurrent exposure to high serum progesterone levels. However, we also observed risk reductions with increasing numbers of incomplete pregnancies. In the first trimester of pregnancy (when most miscarriages and terminations occur), progesterone is elevated to levels that suppress mitoses<sup>4,27,28</sup> but is consistently lower in pregnancies that end in miscarriage than those that continue to term.<sup>29</sup> We found the association did not appear to differ between miscarriages and induced abortions. Furthermore, the risk reduction we observed with an incomplete pregnancy (encompassing perhaps 4-8 weeks of progesterone at levels that would suppress mitoses) was similar in magnitude to the reduction that has been reported for a year of combined oral contraceptive pill

use (~8% reduction per year of use<sup>2</sup>). Notwithstanding our lack of information about gestation duration, these findings suggest that mechanical clearance (eg, via curettage) of endometrial cells may play a role in reducing risk of endometrial cancer.

The reason for the association we observed with off-spring sex and endometrial cancer risk is unclear. Although some studies have indicated that maternal hormone levels vary by offspring sex (eg, higher estradiol<sup>19</sup> and lower progesterone<sup>18</sup> in women carrying female fetuses), others have not<sup>4</sup> and two previous studies showed no difference in endometrial cancer risk according to offspring sex.<sup>30,31</sup> Ours may therefore be a chance finding; hence additional large studies are required to assess this.

## 5 | CONCLUSIONS

In summary, our large analysis, including individual participant data from 30 studies, provides comprehensive evidence that each additional pregnancy is associated with further reductions in endometrial cancer risk, even among grand multiparous women, and that this risk reduction is independent of age at last full-term pregnancy. Furthermore, incomplete pregnancies are also associated with reduced endometrial cancer risk, providing some reassurance to women who experience pregnancy loss that, at least with respect to cancer, their long-term endometrial health is unlikely to be adversely affected.

## ACKNOWLEDGEMENTS AND FUNDING

The funding bodies supported selected authors and participant recruitment and data collection for the individual studies. They had no role in the study design; in the collection, analysis and interpretation of data; in the writing of the report; or in the decision to submit the article for publication.

L. S. Cook held a Canada Research Chair, received AHFMR career award funding and received support from NCI P30CA118100. M. Du and M. C. Pike were supported by the Memorial Sloan Kettering NCI Support Grant P30 CA008748. C. M. Friedenreich received career awards from the Canadian Institutes of Health Research and the Alberta Heritage Foundation for Medical Research (AHFMR) during the conduct of this study. C. La Vecchia was supported by the Italian Foundation for Research in Cancer. A. B. Miller was supported in part by a National Health Scientist Award from Health and Welfare Canada. R. Na was supported by NHMRC Program Grant GNT 1073898. A. B. Spurle was supported by a fellowship from the NHMRC (ID 1061778).

**ALBERTA:** The Canadian Cancer Society.

**ANECS:** The National Health and Medical Research Council (NHMRC) of Australia (APP339435, APP1073898, APP1061341, APP1061779); Cancer Council Tasmania (403031, 457636).

**BAWHS:** The National Institutes of Health (R01 CA74877).

**BCDDP:** Intramural Research Program of the National Cancer Institute/National Institutes of Health, Department of Health and Human Services, United States.

**BWHS:** The National Cancer Institute/National Institutes of Health (R01CA058420, U01CA164974, R03CA169888).

**CNBSS:** This study was supported by funding from the Canadian Breast Cancer Research Alliance, the Canadian Cancer Society, Health and Welfare Canada, the National Cancer Institute of Canada, the Alberta Heritage Foundation for Medical Research, Manitoba Health Services Commission, Medical Research Council of Canada, le Ministère de la Santé et des Services Sociaux du Québec, the Nova Scotia Department of Health, and the Ontario Ministry of Health.

**CONN:** The National Institutes of Health (R01CA098346).

**CTS:** National Institutes of Health (R01CA77398) and the CBCRP fund; the collection of cancer incidence data was supported by the California Department of Public Health as part of the state wide cancer reporting program mandated by California Health and Safety Code Section 103885, the NCI's Surveillance, Epidemiology, and End Results Program awarded to the Cancer Prevention Institute of California, the Public Health Institute, University of Southern California, and the Centers for Disease Control and Prevention's National Program of Cancer Registries.

**EDGE:** The National Institutes of Health (R01 CA083918, P30 CA008748).

**FHCRC:** The National Cancer Institute/National Institutes of Health (R35 CA39779, R01 CA47749, R01 CA75977, N01 HD 23166, K05 CA92002, R01 CA105212, R01 CA87538).

**HAWAII:** This investigation was supported in part by USPHS Grants P01-CA-33619, R01-CA-58598, R01-CA-55700, and P20-CA-57113 and by contracts N01-CN-05223 and N01-CN-55424 from the National Cancer Institute, NIH, Department of Health and Human Services.

**IMS:** The Associazione Italiana per la Ricerca sul Cancro (AIRC).

**IWHS:** The National Institutes of Health (R01 CA39742).

**MEC:** The National Institutes of Health (U01CA164973, RO3CA135632).

**ML1:** The Italian League Against Cancer and the Associazione Italiana per la Ricerca sul Cancro (AIRC).

**ML2:** The Associazione Italiana per la Ricerca sul Cancro (AIRC).

**NLCS:** The Dutch Cancer Society.

**NHS:** The National Cancer Institute/National Institutes of Health (2R01 CA082838 and P01 CA87969).

**NYU:** The National Cancer Institute (R01 CA081212, U01 CA182934 and P30 CA016087) and US National Institute of Environmental Health Sciences (P30 ES000260).

**ORDET:** The Associazione Italiana per la Ricerca sul Cancro (AIRC).

**PEDS:** National Institutes of Health (P30CA016056).

**POL:** Intramural Research Programs of the NCI, NIH, Department of Health and Human Services, United States.

**SECS:** The National Cancer Institute/National Institutes of Health (R01 CA092585).

**SWLHS:** The Swedish Research Council (521-2011-2955).

**TURIN:** The Associazione Italiana per la Ricerca sul Cancro (AIRC).

**USEC:** Intramural Research Programs of the NCI, NIH, Department of Health and Human Services, United States.

**USC:** The National Cancer Institute/National Institutes of Health (R01 CA48774 and P30 CA14089).

**VAUD:** Swiss National Science Foundation grant 32.9495.88 and the Krebsforschung Schweiz Stiftung grant OCS 1633-02-2005.

**WNYDS:** The National Institutes of Health (CA11535).

**WISE:** The National Cancer Institute/National Institutes of Health (P01-CA77596).

## CONFLICT OF INTEREST

Dr. Wise serves as a fibroid consultant for AbbVie, Inc. The other authors declare no conflicts of interests.

## DISCLAIMER

Where authors are identified as personnel of the International Agency for Research on Cancer / World Health Organization, the authors alone are responsible for the views expressed in this article and they do not necessarily represent the decisions, policy or views of the International Agency for Research on Cancer / World Health Organization.

## DATA AVAILABILITY STATEMENT

For privacy and ethical reasons the data are only available through the Epidemiology of Endometrial Cancer Consortium. Consult the corresponding author (penny.webb@qimrberghofer.edu.au) to discuss the access to the Epidemiology of Endometrial Cancer Consortium.

## ETHICS STATEMENT

All studies were approved by the relevant institutional review boards and participants provided informed consent.

## ORCID

Susan J. Jordan <https://orcid.org/0000-0002-4566-1414>

Renhua Na <https://orcid.org/0000-0002-9830-8462>

Elisabete Weiderpass <https://orcid.org/0000-0003-2237-0128>

Kristin E. Anderson <https://orcid.org/0000-0002-5158-5681>

Piet A. van den Brandt <https://orcid.org/0000-0001-8781-8099>

Louise A. Brinton <https://orcid.org/0000-0003-3853-8562>

Chu Chen <https://orcid.org/0000-0003-2267-8050>

Linda S. Cook <https://orcid.org/0000-0002-7917-0082>

Jennifer A. Doherty <https://orcid.org/0000-0002-1454-8187>

Christine M. Friedenreich <https://orcid.org/0000-0002-4783-1966>

Gretchen L. Gierach <https://orcid.org/0000-0002-0165-5522>

Vittorio Krogh <https://orcid.org/0000-0003-0122-8624>

Lingeng Lu <https://orcid.org/0000-0001-9871-0809>

Anthony B. Miller <https://orcid.org/0000-0001-5174-3515>

Susan E. McCann <https://orcid.org/0000-0002-2079-8705>

Eva Negri <https://orcid.org/0000-0001-9712-8526>

Julie R. Palmer <https://orcid.org/0000-0002-6534-335X>

Malcolm C. Pike <https://orcid.org/0000-0003-4891-1199>

Peggy Reynolds <https://orcid.org/0000-0002-5783-7536>

Fulvio Ricceri <https://orcid.org/0000-0001-8749-9737>

Carlotta Sacerdote <https://orcid.org/0000-0002-8008-5096>

Leo J. Schouten <https://orcid.org/0000-0003-3361-7560>

Diego Serraino <https://orcid.org/0000-0003-0565-8920>

Veronica W. Setiawan <https://orcid.org/0000-0001-9239-5692>

Xiao-Ou Shu <https://orcid.org/0000-0002-0711-8314>

Amanda B. Spurdle <https://orcid.org/0000-0003-1337-7897>  
 Rachael Z. Stolzenberg-Solomon <https://orcid.org/0000-0003-3698-7006>  
 Britton Trabert <https://orcid.org/0000-0002-1539-6090>  
 Nicolas Wentzensen <https://orcid.org/0000-0003-1251-0836>  
 Lauren A. Wise <https://orcid.org/0000-0003-2138-3752>  
 Herbert Yu <https://orcid.org/0000-0003-3950-4815>  
 Carlo La Vecchia <https://orcid.org/0000-0003-1441-897X>  
 Immaculata De Vivo <https://orcid.org/0000-0002-7185-7402>  
 Wanghong Xu <https://orcid.org/0000-0003-2045-2218>  
 Anne Zeleniuch-Jacquotte <https://orcid.org/0000-0001-9350-1303>  
 Penelope M. Webb <https://orcid.org/0000-0003-0733-5930>

## REFERENCES

- Raglan O, Kalliala I, Markozannes G, et al. Risk factors for endometrial cancer: an umbrella review of the literature. *Int J Cancer*. 2019;145: 1719-1730.
- Dossus L, Allen N, Kaaks R, et al. Reproductive risk factors and endometrial cancer: the European prospective investigation into cancer and nutrition. *Int J Cancer*. 2010;127:442-451.
- Kim JJ, Kurita T, Bulun SE. Progesterone action in endometrial cancer, endometriosis, uterine fibroids, and breast cancer. *Endocr Rev*. 2013;34:130-162.
- Schock H, Zeleniuch-Jacquotte A, Lundin E, et al. Hormone concentrations throughout uncomplicated pregnancies: a longitudinal study. *BMC Pregnancy Childbirth*. 2016;16:146.
- Lambe M, Wuu J, Weiderpass E, Hsieh CC. Childbearing at older age and endometrial cancer risk (Sweden). *Cancer Causes Control*. 1999;10:43-49.
- Hinkula M, Pukkala E, Kyrronen P, Kauppila A. Grand multiparity and incidence of endometrial cancer: a population-based study in Finland. *Int J Cancer*. 2002;98:912-915.
- Bevier M, Sundquist J, Hemminki K. Does the time interval between first and last birth influence the risk of endometrial and ovarian cancer? *Eur J Cancer*. 2011;47:586-591.
- Husby A, Wohlfahrt J, Melbye M. Pregnancy duration and endometrial cancer risk: nationwide cohort study. *BMJ*. 2019;366:I4693.
- Setiawan VW, Pike MC, Karageorgi S, et al. Age at last birth in relation to risk of endometrial cancer: pooled analysis in the epidemiology of endometrial cancer consortium. *Am J Epidemiol*. 2012;176:269-278.
- Parazzini F, La Vecchia C, Negri E, Fedele L, Balotta F. Reproductive factors and risk of endometrial cancer. *Am J Obstet Gynecol*. 1991;164:522-527.
- Parslov M, Lidegaard O, Klintorp S, et al. Risk factors among young women with endometrial cancer: a Danish case-control study. *Am J Obstet Gynecol*. 2000;182:23-29.
- Xu WH, Xiang YB, Ruan ZX, et al. Menstrual and reproductive factors and endometrial cancer risk: results from a population-based case-control study in urban Shanghai. *Int J Cancer*. 2004;108:613-619.
- Brinton LA, Berman ML, Mortel R, et al. Reproductive, menstrual, and medical risk factors for endometrial cancer: results from a case-control study. *Am J Obstet Gynecol*. 1992;167:1317-1325.
- Kalandidi A, Tzonou A, Lipworth L, Gamatsi I, Filippa D, Trichopoulos D. A case-control study of endometrial cancer in relation to reproductive, somatometric, and life-style variables. *Oncology*. 1996;53:354-359.
- Pocobelli G, Doherty JA, Voigt LF, et al. Pregnancy history and risk of endometrial cancer. *Epidemiology*. 2011;22:638-645.
- McPherson CP, Sellers TA, Potter JD, Bostick RM, Folsom AR. Reproductive factors and risk of endometrial cancer. The Iowa Women's health study. *Am J Epidemiol*. 1996;143:1195-1202.
- Brinton LA, Sakoda LC, Lissowska J, et al. Reproductive risk factors for endometrial cancer among polish women. *Br J Cancer*. 2007;96:1450-1456.
- Wuu J, Hellerstein S, Lipworth L, et al. Correlates of pregnancy oestrogen, progesterone and sex hormone-binding globulin in the USA and China. *Eur J Cancer Prev*. 2002;11:283-293.
- Toriola AT, Vaarasmaki M, Lehtinen M, et al. Determinants of maternal sex steroids during the first half of pregnancy. *Obstet Gynecol*. 2011;118:1029-1036.
- Setiawan VW, Yang HP, Pike MC, et al. Type I and II endometrial cancers: have they different risk factors? *J Clin Oncol*. 2013;31: 2607-2618.
- Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. *BMJ*. 2003;327:557-560.
- Stewart GB, Altman DG, Askie LM, Duley L, Simmonds MC, Stewart LA. Statistical analysis of individual participant data meta-analyses: a comparison of methods and recommendations for practice. *PLoS One*. 2012;7:e46042.
- Parazzini F, Negri E, La Vecchia C, et al. Role of reproductive factors on the risk of endometrial cancer. *Int J Cancer*. 1998;76:784-786.
- Strom BL, Schinnar R, Weber AL, et al. Case-control study of postmenopausal hormone replacement therapy and endometrial cancer. *Am J Epidemiol*. 2006;164:775-786.
- Bernstein L, Pike MC, Ross RK, Judd HL, Brown JB, Henderson BE. Estrogen and sex hormone-binding globulin levels in nulliparous and parous women. *J Natl Cancer Inst*. 1985;74:741-745.
- Chubak J, Tworoger SS, Yasui Y, Ulrich CM, Stanczyk FZ, McTiernan A. Associations between reproductive and menstrual factors and postmenopausal sex hormone concentrations. *Cancer Epidemiol Biomarkers Prev*. 2004;13:1296-1301.
- Key TJ, Pike MC. The dose-effect relationship between 'unopposed' oestrogens and endometrial mitotic rate: its central role in explaining and predicting endometrial cancer risk. *Br J Cancer*. 1988;57:205-212.
- Carmina E, Lobo RA. Evaluation of hormonal status. In: Strauss JF, Barbieri RL, eds. *Yen and Jaffe's Reproductive Endocrinology: Physiology, Pathophysiology, and Clinical Management*. 6th ed. Philadelphia, PA: Saunders/Elsevier; 2009:928.
- Ku CW, Allen JC Jr, Lek SM, Chia ML, Tan NS, Tan TC. Serum progesterone distribution in normal pregnancies compared to pregnancies complicated by threatened miscarriage from 5 to 13 weeks gestation: a prospective cohort study. *BMC Pregnancy Childbirth*. 2018;18:360.
- Olsen J, Storm H. Pregnancy experience in women who later developed oestrogen-related cancers (Denmark). *Cancer Causes Control*. 1998;9:653-657.
- Albrektsen G, Heuch I, Thoresen S, Kvale G. Twin births, sex of children and maternal risk of endometrial cancer: a cohort study in Norway. *Acta Obstet Gynecol Scand*. 2008;87:1123-1128.

## SUPPORTING INFORMATION

Additional supporting information may be found online in the Supporting Information section at the end of this article.

**How to cite this article:** Jordan SJ, Na R, Weiderpass E, et al. Pregnancy outcomes and risk of endometrial cancer: A pooled analysis of individual participant data in the Epidemiology of Endometrial Cancer Consortium. *Int. J. Cancer*. 2021;148: 2068-2078. <https://doi.org/10.1002/ijc.33360>